Philip Morris International Inc. Confirms Discussions With Swedish Match AB Regarding Potential Offer
Philip Morris International Inc. (PMI) (NYSE: PM) today confirmed, in response to recent market speculation, that discussions are ongoing between PMI and Swedish Match AB (STO: SWMA) regarding a potential offer for the company.
The discussions are in progress and it is uncertain whether an offer will be made. PMI intends to make no further comment regarding the discussions unless and until it is appropriate to do so.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration (FDA) has authorized the marketing of versions of PMI’s IQOS Platform 1 devices and consumables as Modified Risk Tobacco Products (MRTPs), finding that exposure modification orders for these products are appropriate to promote the public health. As of March 31, 2022, PMI's smoke-free products are available for sale in 71 markets, and PMI estimates that approximately 12.7 million adults around the world excluding Russia and Ukraine, have already switched to IQOS and stopped smoking. With a strong foundation and significant expertise in life sciences, in February 2021 PMI announced its ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to address unmet consumer and patient needs. For more information, please visit www.pmi.com and www.pmiscience.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005878/en/
Contact information
Philip Morris International
Investor Relations:
New York: +1 (917) 663 2233
Lausanne: +41 (0)58 242 4666
Email: InvestorRelations@pmi.com
Media: David Fraser
Lausanne: +41 (0)58 242 4500
Email: David.Fraser@pmi.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Horizon Quantum Computing Raises USD 18.1 million Series A to Advance Quantum Software Development31.3.2023 09:30:00 CEST | Press release
Horizon Quantum Computing,a Singapore-based company building software development tools to unlock the potential of quantum computing hardware, announced today that it has raised USD 18.1 million Series A investment from Sequoia Capital India, Tencent, SGInnovate, Pappas Capital and Expeditions Fund. The investment round will boost the growth of the company, allowing it to strengthen its science and engineering teams to accelerate product development, establish its new engineering centre in Europe and bring Horizon’s unique technology to the market. Horizon Quantum Computing’s total funding now stands at approximately USD 21.3 million. “Quantum computing has the potential to completely change how we think about computing,” says Horizon’s CEO Dr Joe Fitzsimons. “While getting to large scale quantum computing is a daunting challenge, it is undeniable that progress towards that goal is being made. At Horizon, we focus on unlocking the power of future quantum computers, and have made signif
L&T Technology Services and Ansys set up CoE for Digital Twin31.3.2023 09:30:00 CEST | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, and Ansys, a global leader and pioneer of Multiphysics engineering simulation software have signed an MOU to establish the LTTS-Ansys Center of Excellence (CoE) for Digital Twin. The center will support LTTS in demonstrating industry use cases, develop future facing solutions, and enable its customers to optimize design, manufacturing, and supply chain processes. Ansys' Twin Builder solution will allow LTTS to further expand its market share in digital twin areas. The digital twin market is valued at $6.5 billion and is expected to reach $125.7 billion by 2030, growing at a CAGR of 39.48%. The CoE will help LTTS showcase digital twin proofs of concept to its customers and speed up their adoption. The collaboration will enable LTTS to meet the growing demand for digital twin solutions and provide access to emerging talent in the technology market. The joint efforts of Ansys
Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse ® G ApoE4 and Lumipulse ® G Pan-ApoE assays for Research Use Only31.3.2023 08:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for the fully automated LUMIPULSE® G Systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of the E4 isoform of the apolipoprotein E (ApoE4), specifically, and for all isoforms of the same protein (Pan-ApoE), respectively, in human plasma within just 35 minutes. The two new automated blood-based biomarker assays are available for Research Use Only. “One year after the release of the first blood-based biomarkers for Alzheimer’s disease on our robust LUMIPULSE G platform, Fujirebio adds another two markers to its steadily growing portfolio,” said Christiaan De Wilde, CEO of Fujirebio Europe NV and Global Head Neuro Business. “These new assays will further support biomarker research in the field of neurodegenerative diseases, an important mission for Fujirebio.” The Lumipulse G ApoE4
Hai Robotics Wins Innovation Award for Existing Product at Promat 202331.3.2023 04:26:00 CEST | Press release
Hai Robotics, a leading provider of intelligent automated warehousing solutions, has won the MHI Innovation Award for Best Innovation of an Existing Product for their A42T Autonomous Case-handling Robot (ACR). This prestigious award was announced at ProMat 2023, held in Chicago, on Wednesday, March 22nd. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230327005769/en/ The MHI Innovation Award recognizes Hai Robotics for their groundbreaking work in developing advanced equipment for automated storage and retrieval solutions (ASRS) and recognizes the company's commitment to advancing their customer’s success with innovative and cutting-edge technology. The A42T ACR is the first goods-to-person equipment that extends upward allowing facilities to store items up to 10m (32+ feet) high, while remaining independent of any storage medium. It is highly intelligent, able to handle most totes or container sizes and types, even cardboar
Gravity Launches Its New 3D Platformer Game, 'ALTF42' on Steam Early Access31.3.2023 04:00:00 CEST | Press release
Gravity (NASDAQ: GRVY), a global game company, released its new 3D platformer game, 'ALTF42', as an Early Access version on Steam on March 31, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230330005345/en/ ALTF42, the permadeath-style 3D platformer sequel to ALTF4, is now available as an Early Access version on Steam starting from March 31 (Graphic: Gravity) Gravity will take charge of services related to 'ALTF42', a permadeath-style 3D platformer genre game developed by PUMKIM, a Korean game developer, based on the global publishing know-how it has accumulated over the years. ALTF42 is the official follow-up to 'ATLF4' and features an even higher level of difficulty with more dangerous traps than the previous version. The previous one, ALTF4, gained a great popularity from users around the world, topping the list in STOVE review ratings and 70,000 concurrent viewers on Twitch. As the game is named after the shortcut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom